Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast ... 89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast growth factor 21 (FGF21) is developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.684 | -9.35704514364 | 7.31 | 7.31 | 5.9857 | 1082707 | 6.28596445 | CS |
| 4 | -0.244 | -3.55167394469 | 6.87 | 8.1 | 5.9857 | 1034102 | 7.38985421 | CS |
| 12 | -1.164 | -14.9422336329 | 7.79 | 10.72 | 5.9857 | 1038028 | 8.08017468 | CS |
| 26 | -2.394 | -26.5410199557 | 9.02 | 10.72 | 5.9857 | 775641 | 8.14680162 | CS |
| 52 | -4.284 | -39.2667277727 | 10.91 | 16.63 | 5.9857 | 958221 | 9.20263051 | CS |
| 156 | -5.534 | -45.5098684211 | 12.16 | 22.93 | 2 | 1077622 | 10.99228929 | CS |
| 260 | -19.004 | -74.1474834179 | 25.63 | 47.2532 | 2 | 685816 | 11.80177373 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
